1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

  • April 2019
  • 187 pages
  • ID: 5782431
  • Format: PDF
  • Prescient & Strategic Intelligence Private Limited

Summary

Table of Contents

Biosimilars Market By Product (Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, Follitropin], Recombinant Non-Glycosylated Proteins [Insulin, Recombinant Human Growth Hormone, Granulocyte-Colony Stimulating Factor, Interferons], Recombinant Peptides), By Technology (Monoclonal Antibody, Recombinant DNA, Bioassays, Nuclear Magnetic Resonance, Electrophoresis), By Indication (Oncology, Rheumatology, Blood-Related Disorders, Auto-Immune Diseases, Chronic Diseases, Infectious Diseases, Growth Hormone Deficiency), By Manufacturing Type (Contract, In-House), By Route of Administration (Intravenous, Subcutaneous, Intranasal), by Geography (Germany, France, U.K., Italy, Spain, Sweden, Russia, Switzerland, Austria, Netherlands, Belgium, Norway, China, Japan, India, South Korea, Singapore, Australia, Thailand, Indonesia, Malaysia, U.S., Canada, Brazil, Mexico, Argentina, Columbia, U.A.E., Israel, South Africa, Saudi Arabia) - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

The biosimilars market is predicted to reach $26.7 billion by 2024, progressing at a CAGR of 29.6% during the forecast period (2019–2024), according to the report. The market is driven by the rising prevalence of chronic disease, growing investment in research and development by biopharmaceutical organizations, vast pipeline of biosimilars, surging geriatric population, and the cost-efficient nature of biosimilars as compared to approved drugs.

Based on technology, the biosimilars market is classified into monoclonal antibody (mAb), bioassays, nuclear magnetic resonance (NMR), recombinant deoxyribonucleic acid (rDNA), and electrophoresis. Biosimilars manufactured using the mAb technology held 56.0% share in the market in 2018. This technology is further anticipated to be the fastest growing due to its large-scale deployment in the development of therapeutics to treat various diseases, such as immunological, cancer, and infections.

On a global ground, in 2018, Europe dominated the biosimilars market with nearly 47.7% share. This is ascribed to the flexible regulatory parameters, surging aging population, and increasing R&D investments by biopharmaceutical organizations in the region.

The biosimilars market is expected to observe the fastest growth in North America, progressing at CAGR of 32.7% during the 2019–2024 period. This can be mainly attributed to the surging geriatric population, increasing prevalence of chronic diseases, and growth in R&D investments.

Companies in North America have more freedom to price their products as they want compared to other regions, and advanced technologies and trained scientific personnel are readily available in here, which make it ideal for pharmaceutical companies.

According to the Population Reference Bureau report, titled Aging in the United States, the aging population is anticipated to double by 2060, resulting in the need for old age-related disease management. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 60.0% of the adults in the U.S. are suffering from one or more chronic diseases.

Strategic collaborations and product launches play a prominent role in the growth of the biosimilars market. For instance, Amgen Inc. and Entera Bio Ltd. collaborated in 2018 to launch an orally administered formulation of biologics. This collaboration shows that organizations are ready to invest in biologics, resulting in the growth of the market.

Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the business of biosimilars in China. With the collaboration, Samsung Bioepis Co. Ltd. will seek to enlarge its biosimilars portfolio, while 3SBio Group will be supported by the sales of Avastin.

Some of the key players operating in the market, globally, are Samsung Bioepis Co. Ltd., AMEGA Biotech, Synthon Holding B.V., Coherus BioSciences Inc., Celltrion Inc., BIOCAD, Zydus Cadila, Teva Pharmaceutical Industries Limited, Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.

Global Biosimilars Market Segmentation
Market Segmentation by Product
• Recombinant Glycosylated Proteins

- Monoclonal antibodies (mAbs)
- Erythropoietin
- Follitropin

• Recombinant Non-Glycosylated Proteins

- Insulin
- Recombinant human growth hormone
- Granulocyte-colony stimulating factor (G-CSF)
- Interferons

• Recombinant Peptides

Market Segmentation by Technology
• Monoclonal Antibody (mAb)
• Recombinant Deoxyribonucleic Acid (rDNA)
• Bioassays
• Nuclear Magnetic Resonance (NMR)
• Electrophoresis

Market Segmentation by Indication
• Oncology
• Rheumatology
• Blood-Related Disorders
• Auto-Immune Diseases
• Chronic Diseases
• Infectious Diseases
• Growth Hormone Deficiency (GHD)
• Others

Market Segmentation by Manufacturing Type
• Contract
• In-House

Market Segmentation by Route of Administration (ROA)
• Intravenous
• Subcutaneous
• Intranasal
• Others

Market Segmentation by Geography
• Europe Biosimilars Market

- By product
- By technology
- By indication
- By manufacturing type
- By ROA
- By country – Germany, France, U.K., Italy, Spain, Sweden, Russia, Switzerland, Austria, Netherlands, Belgium, Norway, and Rest of Europe

• Asia-Pacific (APAC) Biosimilars Market

- By product
- By technology
- By indication
- By manufacturing type
- By ROA
- By country – China, Japan, India, South Korea, Singapore, Australia, Thailand, Indonesia, Malaysia, and Rest of APAC

• North America Biosimilars Market

- By product
- By technology
- By indication
- By manufacturing type
- By ROA
- By country – U.S. and Canada

• Latin America (LATAM) Biosimilars Market

- By product
- By technology
- By indication
- By manufacturing type
- By ROA
- By country – Brazil, Mexico, Argentina, Columbia, and Rest of LATAM

• Middle East & Africa (MEA) Biosimilars Market

- By product
- By technology
- By indication
- By manufacturing type
- By ROA
- By country – U.A.E., Israel, South Africa, Saudi Arabia, and Rest of MEA

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Biosimilars Market Research Report by Indication, by Product, by Manufacturing, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 193 pages

Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, and Chronic Diseases), by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and ...

  • World
  • Protein Therapy
  • Monoclonal Antibody
  • Industry analysis

ref:plp2019

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on